| HDAC2 promotes autophagy-associated HCC malignant progression by transcriptionally activating LAPTM4B. | HDAC2 promotes autophagy-associated HCC malignant progression by transcriptionally activating LAPTM4B.
Wang M, Liao J, Wang J, Xu M, Cheng Y, Wei L, Huang A., Free PMC Article | 09/26/2024 |
| LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy. | LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.
Wang H, Zhou Q, Xie DF, Xu Q, Yang T, Wang W., Free PMC Article | 02/28/2024 |
| LAPTM4B promotes AML progression through regulating RPS9/STAT3 axis. | LAPTM4B promotes AML progression through regulating RPS9/STAT3 axis.
Huang Y, Peng M, Qin H, Li Y, Pei L, Liu X, Zhao X. | 04/12/2023 |
| Screening of four key genes in esophageal carcinoma based on TCGA and GEO data and verification of anti-proliferative effect of LAPTM4B knockdown in esophageal carcinoma cells invitro. | Screening of four key genes in esophageal carcinoma based on TCGA and GEO data and verification of anti-proliferative effect of LAPTM4B knockdown in esophageal carcinoma cells invitro.
Guo K, Li K. | 09/3/2022 |
| [Serum LAPTM4B-35 protein as a novel diagnostic marker for hepatocellular carcinoma]. | [Serum LAPTM4B-35 protein as a novel diagnostic marker for hepatocellular carcinoma].
Pang Y, Zhang S, Yang H, Zhou RL., Free PMC Article | 09/18/2021 |
| LAPTM4B controls the sphingolipid and ether lipid signature of small extracellular vesicles. | LAPTM4B controls the sphingolipid and ether lipid signature of small extracellular vesicles.
Dichlberger A, Zhou K, Bäck N, Nyholm T, Backman A, Mattjus P, Ikonen E, Blom T. | 04/24/2021 |
| Lysosomal-associated transmembrane protein 4B regulates ceramide-induced exosome release. | Lysosomal-associated transmembrane protein 4B regulates ceramide-induced exosome release.
Yuyama K, Sun H, Mikami D, Mioka T, Mukai K, Igarashi Y. | 04/24/2021 |
| Overexpression of LAPTM4B-35 is a negative prognostic factor in head and neck squamous cell carcinoma. | Overexpression of LAPTM4B-35 is a negative prognostic factor in head and neck squamous cell carcinoma.
Kotowski U, Kadletz L, Schneider S, Oberndorfer F, Schnoell J, Gurnhofer E, Kenner L, Lucas T, Heiduschka G., Free PMC Article | 01/2/2021 |
| Lysosome Associated Protein Transmembrane 4B-24 Is the Predominant Protein Isoform in Human Tissues and Undergoes Rapid, Nutrient-Regulated Turnover. | Lysosome Associated Protein Transmembrane 4B-24 Is the Predominant Protein Isoform in Human Tissues and Undergoes Rapid, Nutrient-Regulated Turnover.
Zhou K, Dichlberger A, Ikonen E, Blom T. | 11/21/2020 |
| Epithelial-to-mesenchymal transition in Gastric Cancer is promoted by a combination of LAPTM4B overexpression and H. pylori infection. | Helicobacter pylori infection promotes epithelial-to-mesenchymal transition of gastric cells by upregulating LAPTM4B.
Zhou S, Chen H, Yuan P, Shi N, Wang X, Hu J, Liu L. | 06/20/2020 |
| Lysosome-associated transmembrane protein 4B (LAPTM4B) is overexpressed in triple-negative breast cancer. The knockdown of LAPTM4B restores cyclin-dependent kinase inhibitor p27 (p27kip1) expression and inhibits the aggressiveness of breast cancer cells. | Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer.
Li X, Song C, Wang K, Li N, Sun S, Li N, Zhao Z, Li M. | 11/23/2019 |
| In the current study, we performed a meta-analysis to find out the exact role of LAPTM4B polymorphism on risk of cancer. The results revealed that LAPTM4B polymorphism significantly increased the risk of cancer in codominant, dominant, overdominant, and allele genetic inheritance models | LAPTM4B gene polymorphism augments the risk of cancer: Evidence from an updated meta-analysis.
Hashemi M, Bahari G, Tabasi F, Markowski J, Małecki A, Ghavami S, Łos MJ., Free PMC Article | 11/2/2019 |
| Results show that LAPTM4B expression breast cancer cells is inversely correlated and regulated by mir-132 which bind to its 3'UTR. | MicroRNA-132-3p inhibits tumor malignant progression by regulating lysosomal-associated protein transmembrane 4 beta in breast cancer.
Li S, Xu JJ, Zhang QY., Free PMC Article | 10/12/2019 |
| LAPTM4B is related to lung adenocarcinoma (LAC) progression and might be a potential biomarker and theraputic target for LAC. | LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR.
Wang L, Meng Y, Zhang QY., Free PMC Article | 09/7/2019 |
| Results confirm the possible role of the LAPTM4B gene in anthracycline resistance in HR- breast cancer. | LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.
Rusz O, Papp O, Vízkeleti L, Molnár BÁ, Bende KC, Lotz G, Ács B, Kahán Z, Székely T, Báthori Á, Szundi C, Kulka J, Szállási Z, Tőkés AM. | 06/29/2019 |
| LAPTM4B-35 is significantly deregulated in PDAC with high diagnostic and prognostic impact as circulating tumor marker. | Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z, Senninger N, Flammang I, Ye Q, Dhayat SA. | 05/11/2019 |
| AP4 and LAPTM4B are highly coexpressed in hepatocellular carcinoma tissues, and their coexpression may be a marker of poor prognosis. | AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity.
Meng Y, Wang L, Xu J, Zhang Q., Free PMC Article | 02/23/2019 |
| Findings identify LAPTM4B as a direct AP4 target gene and the interaction of AP4 and LAPTM4B plays an important role in breast cancer progression.Implications: This study demonstrates that AP4 promotes cell growth, migration, invasion, and cisplatin resistance through upregulation of LAPTM4B expression. | The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression.
Wang L, Meng Y, Xu JJ, Zhang QY. | 02/23/2019 |
| our results illustrate the LAPTM4B gene as a diagnostic biomarker in patients with hepatocellular carcinoma having documented evidence of chronic hepatitis C virus infection | Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma.
Roy G, Roy P, Bhattacharjee A, Shahid M, Misbah M, Gupta S, Husain M. | 11/10/2018 |
| that LAPTM4B plays an important role in the promotion of hepatocarcinogenesis and cancer progression and may serve as a biomarker for the diagnosis and monitoring of hepatocellular carcinoma | Correlation of lysosome-associated protein transmembrane-4β gene overexpression with the malignant phenotypes of hepatocellular carcinoma.
Su H, Xu T, Huang X, Zang S, Wang B, Huang Y, Liu J, Huang A. | 08/11/2018 |
| Findings suggest that lysosome-associated transmembrane protein 4B (LAPTM4B), vascular endothelial growth factor (VEGF), and nuclear survivin expression are significantly correlated in breast cancer, which may be predictive of prognosis as well as effective therapeutic targets for anticancer therapies. | Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.
Li S, Wang L, Meng Y, Chang Y, Xu J, Zhang Q., Free PMC Article | 04/14/2018 |
| LAPTM4B-35 is a novel cancer-driving protein that can be inhibited by ethylglyoxal bisthiosemicarbazon | Targeting a novel cancer-driving protein (LAPTM4B-35) by a small molecule (ETS) to inhibit cancer growth and metastasis.
Li M, Zhou R, Shan Y, Li L, Wang L, Liu G., Free PMC Article | 02/24/2018 |
| The overexpressed LAPTM4B-35 was an independent prognostic biomarker for non-small-cell lung cancer, which could predict cancer recurrence and poor over survival. | Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F, Gao F, Chen J, Sun Y, Zhang Y, Liu H, Li X, Yang P, Zheng R, Liu G, Jia Y., Free PMC Article | 01/20/2018 |
| The findings of this study showed LAPTM4B-35 to be strongly associated with tumor proliferation, tumor angiogenesis and poor outcomes of GBM patients. | LAPTM4B-35 is a novel prognostic factor for glioblastoma.
Dong X, Tamura K, Kobayashi D, Ando N, Sumita K, Maehara T. | 12/30/2017 |
| Findings suggested that LAPTM4B allele *1 was a risk factor associated with poor prognosis in patients with colon cancer, but not in patients with rectal or esophageal cancers. LAPTM4B genotype status might be a useful prognostic indicator for patients that need surgical operation in colon cancer. | Relationship between LAPTM4B Gene Polymorphism and Prognosis of Patients following Tumor Resection for Colorectal and Esophageal Cancers.
Cheng X, Tian X, Wu X, Xing X, Du H, Zhou C, Zhang Q, Hao C, Wen X, Ji J., Free PMC Article | 08/19/2017 |